Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > 130 Million Shares of 500+ float ; Bought by Salzman Group📈

<< Previous

Bullboard Posts

Next >>

Comment by PowerofNowon Apr 07, 2021 2:25pm

245 Views

Post# 32950595

RE:130 Million Shares of 500+ float ; Bought by Salzman Group📈

Loving the LOW VOLUME. Proving that no one is selling @.04 cents this tight squeeze is going to be very interest !

SalzmanGroup wrote: Takes about 1200 people holding 500k shares to take out entire float !! HUGE insider ownership POP.

issuance of 130 million common shares of the Company to the Salzman Group.

Salzman Group, Ltd., an Israeli corporation, and Salzman Group Pty Ltd., an Australian corporation (collectively the "Salzman Group"), and Kalytera Therapeutics, Inc. (the "Company"), whereby the Company may acquire a license to develop and commercialize R-107 with a license fee of US$1.2 million and the issuance of 130 million common shares of the Company to the Salzman Group. Further considerations include *--a success fee of US $2 million based on certain milestone and additional milestone payments in stages in the cash amount of US$4,250,000 !!!!! --*